Polycarboxylic Acid Or Salt Thereof Patents (Class 514/574)
-
Publication number: 20100215723Abstract: A wound dressing (500) includes a flexible layer of material (501) that is treated with an antimicrobial agent (604), such as PHMB. The antimicrobial agent (604) ionically bonds to cellulose fibers (502) of the flexible layer of material (501) through a bonding agent (601). The bonding agent (601) increases the number of available carboxylate bonding groups beyond a characteristic carboxylate bonding group density normally associated with untreated cellulose fiber such that more antimicrobial agent (604) can be bonded to the flexible layer of material (501). An optional antifungal agent (606) can also be applied to the flexible layer of material (501).Type: ApplicationFiled: February 20, 2009Publication date: August 26, 2010Inventor: Min Yao
-
Patent number: 7771736Abstract: Protozoan parasites of the phylum Apicomplexa include some of the most important causative agents of human and animal diseases, in particular, malaria. The discovery that an organelle found inside parasites of this phylum probably stems from a plastid of plant origin has stimulated research on the effect of chemical herbicidal agents on Apicomplexa. Importantly, the growth of these parasites can be inhibited by the herbicide glyphosate, suggesting that the shikimate pathway will make a good target for the development of new anti-parasite agents. The present invention discloses the use of the herbicidal agent glyphosate in combination with the polyvalent anion oxalic acid for the prevention and therapy of these pathogenic infections.Type: GrantFiled: August 29, 2003Date of Patent: August 10, 2010Assignee: Monsanto Technology LLCInventor: William Abraham
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20100189611Abstract: This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.Type: ApplicationFiled: April 2, 2010Publication date: July 29, 2010Applicant: The Clorox CompanyInventors: David Lestage, David R. Scheuing, Scott L. Cumberland, Grant Templin
-
Publication number: 20100187263Abstract: This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.Type: ApplicationFiled: April 2, 2010Publication date: July 29, 2010Applicant: The Clorox CompanyInventors: David Lestage, David R. Scheuing, Scott L. Cumberland, Grant Templin
-
Publication number: 20100189809Abstract: This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.Type: ApplicationFiled: April 2, 2010Publication date: July 29, 2010Applicant: The Clorox CompanyInventors: David Lestage, David R. Scheuing, Scott L. Cumberland, Grant Templin
-
Publication number: 20100184643Abstract: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.Type: ApplicationFiled: August 22, 2007Publication date: July 22, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Adam N. Goldfarb, Loretta L. Delehanty
-
Patent number: 7759396Abstract: A method for manufacturing an antineoplastic preparation containing alpha-ketoglutarate (AKG) or/and glutamine or/and glutamate or/and alpha-ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid, or/and mono- and divalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-ketoglutarate.Type: GrantFiled: January 10, 2006Date of Patent: July 20, 2010Assignee: SGP & Sons ABInventors: Stefan Pierzynowski, Martyna Kandefer-Szerszen, Wojciech Rzeski
-
Patent number: 7759334Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.Type: GrantFiled: June 27, 2007Date of Patent: July 20, 2010Assignee: Pharmaceutical Solutions, Inc.Inventors: Michael A. Strobel, Pat Soderlund, Jr.
-
Publication number: 20100173014Abstract: The instant invention discloses methods of preparing phospholipid delivery systems encapsulating one or more bio-affecting compounds, said methods comprising solubilizing a heterogeneous phospholipid mixture into a suitable organic solvent to form a concentrated formulation of phospholipids, wherein the phospholipids comprise a charged phospholipid species, and mixing the concentrated formulation with an aqueous solution comprising at least one bio-affecting compound. The instant invention also discloses methods of using a phospholipid delivery system encapsulating at least one bio-affecting compound for administration to an individual in need thereof.Type: ApplicationFiled: May 24, 2007Publication date: July 8, 2010Applicant: Nanosolutions, LLCInventor: Michael W. Fountain
-
Patent number: 7749529Abstract: This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention includes citrate and a paraben. The solution preferably has a density suitable for retention of the solution in a catheter during the lock period. Another lock solution provided by the invention includes citrate, a paraben and a photo-oxidant, such as, for example, methylene blue.Type: GrantFiled: February 8, 2005Date of Patent: July 6, 2010Assignee: Ash Access Technology, Inc.Inventors: Stephen R. Ash, Janusz Steczko, Gary L. Swanson
-
Publication number: 20100166886Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.Type: ApplicationFiled: March 12, 2010Publication date: July 1, 2010Inventors: Jeffrey M. Wu, Jue-Chen Liu, Jeannette Chantalat, Ying Sun, Stefanie A. Johnsen, Hanuman B. Jampani
-
Publication number: 20100160440Abstract: The present invention relates to intranasal pharmaceutical compositions for preventing and/or treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, cerebral ischemia and neurological damage due to stroke comprising a therapeutically effective amount of succinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically and intranasally acceptable carrier. Further, the present invention relates to methods for preventing and/or treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, cerebral ischemia and neurological damage due to stroke with using compositions of the present invention.Type: ApplicationFiled: August 2, 2007Publication date: June 24, 2010Inventor: Igor Anatolievich Pomytkin
-
Patent number: 7741370Abstract: This invention relates to new double salts of (?)-hydroxycitric acid with group II metals. Preferred double salts are calcium and magnesium double salts of hydroxycitric acid of the formula II. This invention also includes a process for the preparation of these double salts by the addition of one metal compound from group II to (?)-hydroxycitric acid solution followed by the addition of other metal compound solution from group II. These double salts are tasteless and are soluble in water. They are useful as dietary supplements and in beverages.Type: GrantFiled: April 19, 2004Date of Patent: June 22, 2010Assignee: Laila ImpexInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Subbaraju Gottumukkala, Venkateswarlu Somepalli
-
Publication number: 20100150895Abstract: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, ?-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O2.Type: ApplicationFiled: February 6, 2010Publication date: June 17, 2010Inventors: Elizabeth Mazzio, Karam Soliman
-
Patent number: 7737179Abstract: A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.Type: GrantFiled: August 2, 2004Date of Patent: June 15, 2010Assignee: J&J Consumer Companies, Inc.Inventors: Bing Wang, Sekhar Bodupalli, Xiangfeng Li, Khalid Mahmood, Wei Zhang, Guy Miller
-
Publication number: 20100140368Abstract: A foaming insecticidal ant spray is described that minimally comprises an essential oil, an emulsifier, a carboxylate salt and water, which has maximum mortality on ants. A method for killing and controlling ants is described wherein the composition is foamed directly onto the ants whereby the ants become entangled within the foam, increase their contact time with the compositions, and perish.Type: ApplicationFiled: June 23, 2008Publication date: June 10, 2010Applicant: The Dial CorporationInventors: Frederique M. de Lame, James Crucitt, Richard Merwin, Mike Wong
-
Publication number: 20100144737Abstract: The present invention relates to methods and compounds useful for inhibiting T helper cell differentiation. Methods and compounds for decreasing IL-12 signaling in T helper cells are also provided.Type: ApplicationFiled: December 8, 2008Publication date: June 10, 2010Applicant: FibroGen, Inc.Inventors: Felice Aisha Chow, Stephen J. Klaus, Ingrid Langsetmo Parobok
-
Publication number: 20100143491Abstract: It is intended to provide an organic peracid polymer composition which is stable, odorless and has sufficient water solubility and is suitably used as a bactericide, a bleaching agent and a cleaning agent. By mixing and dissolving an organic acid polymer, hydrogen peroxide and an inorganic acid and maintaining the mixture for a period ranging from 1 hour to 1 month at a temperature ranging from 10 to 80° C., the organic peracid polymer-containing composition containing an organic peracid polymer (2 to 50% by weight) and, in some cases, the hydrogen peroxide (2 to 50% by weight) and the inorganic acid (0.1 to 10% by weight) is obtained.Type: ApplicationFiled: July 18, 2006Publication date: June 10, 2010Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Yasunari Kawabata, Yasushi Hiramatsu
-
Publication number: 20100137444Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: June 26, 2009Publication date: June 3, 2010Inventors: Jean-Louis Henri Dasseux, Daniela Carmen Oniciu
-
Publication number: 20100136141Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.Type: ApplicationFiled: July 13, 2009Publication date: June 3, 2010Inventors: Gary J. Pond, John Baeten
-
Patent number: 7727517Abstract: This invention relates to a stabilized honey bee pheromone and methods of stabilizing the honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized pheromone can be used to manipulate the behavior and improve the performance of worker honey bees, resulting in overall increased vigor of the hive. The pheromone composition comprises two or more of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl linolenate, methyl oleate, methyl palmitate and methyl stearate and an antioxidant.Type: GrantFiled: September 7, 2006Date of Patent: June 1, 2010Assignee: Contech Enterprises Inc.Inventors: Tanya Pankiw, Jean Pierre Lafontaine, Norman Avelino
-
Publication number: 20100130607Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: February 7, 2008Publication date: May 27, 2010Inventor: Ralf Gold
-
Publication number: 20100124537Abstract: The invention relates to a new use of alpha-ketoglutarate for manufacturing of medical preparation for prophylaxis or treatment of undesired medical conditions associated with the presence and/or activity of ureolytic bacteria in living organisms, except plants, including a human being, pet and farm animal, such as mammal, bird, amphibian, fish, molluse or arthropod, whereas the undesired medical conditions is a condition associated with the presence and/or activity in the gastrointestinal tract, respiratory and/or urogenital system of ureolytic bacteria from the group including Helicobacter pylori, bacterial strains from the Brucella genus, urease-positive bacteria such as Ureaplasma ureolyticum and other alkalophilic bacteria, such as for instance Bacillus pasteurii, urease-producing Yersinia enterocolica rods, ureolytic bacteria that participate in the formation of biofilm and mineralisation of deposits on catheters and other medical equipment, ureolytic bacteria causing infections of the mucous membrane iType: ApplicationFiled: July 3, 2007Publication date: May 20, 2010Inventor: Danuta KRUSZEWSKA
-
Publication number: 20100119608Abstract: Among natural mechanisms of cell deaths, disease or toxicity, one of the most common method is through overloading of certain biological metals such as calcium, iron and zinc. We propose to utilize this natural mechanism of cell death against cancer by utilizing the well known phenomenon of enhanced permeation and retention effect (EPR effect) and metal-binding nanoparticle moieties that can self-degrade under certain biological conditions such as pH. More specifically, we show that one can form nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium, displaying acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher.Type: ApplicationFiled: November 11, 2008Publication date: May 13, 2010Inventor: Jinhyuk Fred Chung
-
Publication number: 20100119621Abstract: A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range of 3 to 40 ?m, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii) mixing the calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and dying the resulting mixture to produce a first granulate; (iii) optionally mixing the first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing the first or second granulate to form tablets.Type: ApplicationFiled: November 13, 2009Publication date: May 13, 2010Applicant: Nycomed Pharma ASInventors: Jan Yngvar Piene, Dina Dogger Schmidt
-
Publication number: 20100113599Abstract: The present invention relates to the use of at least one long-chain optionally-substituted amphipatic carboxylates (known as MEDICA drugs) or any salt, ester or amid thereof or any combination or mixture thereof, for the treatment and prevention of immune-related disorders, particularly, inflammatory conditions. More specifically, the invention relates to particular analogs of these MEDICA drugs, the 3,3,14,14 tetramethyl-hexadecanedioic acid (M16??), 4,4,15,15 tetramethyl-octadecanedioic acid (M18??) and 2,2,15,15-tetramethyl-hexadecanedioic acid (M16??). The invention further provides methods, oral compositions and kits for the treatment and prevention of immune-related disorders using these MEDICA drugs. The disease is any one of multiple sclerosis, neurodegenerative disease, an atherosclerotic disease, inflammatory bowel diseases, arthritis.Type: ApplicationFiled: February 26, 2008Publication date: May 6, 2010Applicant: Syndromex Ltd. c/o Yissum Research Development Company, ofInventor: Jacob Bar-Tana
-
Publication number: 20100105776Abstract: The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C23H25N2)—(C2HO4)]2—C2H2O4 of the following structural formula as a drug for treating malignant neoplasms administered in a single doze of 1 to 2 g. Malachite green can be used when dissolved in an aqueous solution or in a physiological salt solution or in spirit. In different cases, the malachite green solution is perorally administered before and after a meal or is injected per rectum, or a 1% malachite green solution is intravenously introduced, or the malachite green is applied as a rectal suppository component or as a component of 1-5% ointment. The medicinal agent exhibits an extended range of therapeutic actions with respect to different oncological diseases, is freely available, not expensive, non-toxic, does not generate side effects when used in pharmaceutically acceptable doses, and makes it possible to reduce a treating time and to increase the efficiency of treatment.Type: ApplicationFiled: November 29, 2006Publication date: April 29, 2010Inventor: Mikhail Vladimirovich Kutushov
-
Publication number: 20100069338Abstract: The present invention provides a composition for topical administration to the skin for treating and/or preventing a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells comprising a zinc salt which is at least partially soluble in water and an acid, wherein the composition has a pH less than or equal to 6. The dermatological condition is generally selected from eczema, dermatitis, atopic eczema, atopic dermatitis, non-atopic eczema, non-atopic dermatitis, seborrheic eczema, irritant contact dermatitis, allergic contact dermatitis, pruritus and sensitive skin. A preferred composition comprises zinc lactate, lactic acid and has a pH of about 4.0 to 5.0.Type: ApplicationFiled: August 31, 2007Publication date: March 18, 2010Applicant: YORK PHARMA PLCInventors: Simon J. Ward, Alice MacGowan, Michael J. Cork, Adrian Davis
-
Publication number: 20100069335Abstract: An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer. Most preferably, the metal chelator is EDTA or a salt of EDTA, and the transport enhancer is methylsulfonylmethane (MSM). The formulation may be in a form suitable for application to the eye itself, for example, in the form of eye drops.Type: ApplicationFiled: November 13, 2009Publication date: March 18, 2010Inventors: Rajiv Bhushan, Jerry B. Gin
-
Publication number: 20100069498Abstract: A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof. Also contemplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof, for decreasing glucose adsorption as well as compositions for use in treatment.Type: ApplicationFiled: November 25, 2009Publication date: March 18, 2010Applicant: ESSENTYS ABInventors: Stefan G. PIERZYNOWSKI, Douglas Burrin
-
Patent number: 7674824Abstract: A storage stable pharmaceutical composition comprising a solution of Oxaliplatin in water and a catalytic amount of a carbohydrate. A process for forming such pharmaceutical composition comprising dissolving a known amount of Oxaliplatin in water; adding an amount of carbohydrate in the range of 0.0010% to 0.05% w/v with respect to such solution; agitating the mixture to get clear solution; filtering it through a filter membrane under aseptic conditions; and filling the solution resulting into glass vials sealed with elastomeric stoppers and aluminium flip-off seals.Type: GrantFiled: September 5, 2006Date of Patent: March 9, 2010Assignee: Fresenius Kabi Oncology LimitedInventors: Satish Chandra Upadhyay, Manoj Kumar Pananchukunnath, Ajeet Kumar Singh, Deepti Jain, Deepak Judgelal Parshotamdas, Rama Mukharjee, Anand C Burman
-
Publication number: 20100056974Abstract: The present invention has as an object to provide a bone metabolism improving agent that improves bone metabolism in a chronic renal failure patient receiving blood purification therapy such as hemodialysis, hemofiltration and hemodiafiltration. An acetic acid- and/or acetate salt-free bone metabolism improving agent that contains citric acid and/or a citrate salt as electrolytes and further contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. A bone metabolism improving agent formulated into a dialysate or a substitution fluid having effects of improving bone metabolism including bone metabolism improvement in adynamic bone disease and especially in bone agenesis is also provided.Type: ApplicationFiled: September 11, 2009Publication date: March 4, 2010Applicant: AJINOMOTO CO. INCInventors: Hidehiro YAMAZAKI, Toshihiro Ohki, Tomio Inaba, Naomi Sakaguchi
-
Publication number: 20100048696Abstract: The present invention provides a disinfectant comprising as an active ingredient maleic acid and/or maleic anhydride.Type: ApplicationFiled: January 11, 2008Publication date: February 25, 2010Applicant: Idemitsu Kosan Co., Ltd.Inventors: Kazuo Sumi, Kazuyoshi Koike, Shinji Ito
-
Patent number: 7666908Abstract: The present invention relates to method for enhancing cognitive function in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of the formula (I): Further, the present invention provides a method for treating a disorder of cognitive function in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of the formula (I):Type: GrantFiled: January 24, 2006Date of Patent: February 23, 2010Inventors: Igor Anatolievich Pomytkin, Pavel Vasilievich Verteletsky
-
Publication number: 20100040701Abstract: A novel exfoliating compound and method for treating acne without an irritating cleanser. The compound includes a first subcompound formed from a clay based substance and a second subcompound formed an exfoliating substance selected from the group consisting of crystals, beads, polyethylene, nuts, natural rough products, corundum crystals, crushed almond shells and crushed apricot kernels.Type: ApplicationFiled: August 10, 2009Publication date: February 18, 2010Inventor: Neal Schwartz
-
Publication number: 20100035994Abstract: The present invention relates to a novel hydrate form of O-desmethyl venlafaxine succinate. The present invention further relates to processes for the preparation of the novel hydrate form, pharmaceutical compositions comprising it, second medical uses of the novel hydrate form, and methods using it for treating diseases such as generalised anxiety disorder, anxiety, depressive disorder, depression and panic disorder.Type: ApplicationFiled: August 8, 2007Publication date: February 11, 2010Inventors: Vinayak G. Gore, Vikas S. Kulkarni, Vikas S. Wakchaure, Mahesh G. Hublikar, Sneha R. Wavhal
-
Publication number: 20100028402Abstract: A method for preventing or treating a blood clotting disorder is disclosed. The method includes administering a therapeutic effective amount of at least one nanoparticle-based anticoagulant to a subject afflicted with blood clotting disorder or potentially afflicted with a blood clotting disorder, wherein the at least one nanoparticle-based anticoagulant is a substituted fullerene, polyamidoamine (PAMAM) dendrimer or combination thereof.Type: ApplicationFiled: October 25, 2006Publication date: February 4, 2010Inventors: Marina Dobrovolskaia, Scott McNeil, Barry W. Neun
-
Publication number: 20100021526Abstract: The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.Type: ApplicationFiled: October 7, 2009Publication date: January 28, 2010Applicant: MONOSOL RX, LLCInventors: GARRY L. MYERS, PRADEEP SANGHVI
-
Publication number: 20100016434Abstract: The present invention provides methods for preventing or reducing neuronal apoptosis, particularly wherein the apoptosis is associated with a neurodegenerative disorder in a subject.Type: ApplicationFiled: July 13, 2006Publication date: January 21, 2010Inventors: William G. Kaelin, JR., Archana Bommi-Reddy, Susanne Schlisio
-
Publication number: 20100016438Abstract: A composition made of pure natural minerals that can be used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal benefits.Type: ApplicationFiled: July 19, 2008Publication date: January 21, 2010Inventor: Daniel Hassani
-
Patent number: 7645742Abstract: A composition for enhancing cellular energy that includes creatine, L-arginine-?-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.Type: GrantFiled: June 22, 2005Date of Patent: January 12, 2010Assignee: Advocare International, L.P.Inventor: Sidney Stohs
-
Publication number: 20100004338Abstract: The present invention discloses a novel azelaic acid topical pharmaceutical gel composition that does not contain lecithin and a process for its preparation.Type: ApplicationFiled: June 30, 2009Publication date: January 7, 2010Applicant: GLENMARK GENERICS LTD.Inventors: Nilendu Sen, Olympia Noronha
-
Publication number: 20090311327Abstract: The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.Type: ApplicationFiled: November 28, 2006Publication date: December 17, 2009Applicant: IMAGINOT PTY LTDInventors: Michael Stephen Roberts, George Alexander Davidson, Ruoying Jiang, Geraldine Ann Elliott, Keivan Bezanehtak, Stephen Douglas Chandler, Greg Davey, Mantu Sarkar
-
Publication number: 20090312427Abstract: Use of a substance for treating medical joint conditions, e.g. arthrosis, rheumatoid arthritis and cartilage impairment. The use includes the use of alpha-ketoglutaric acid, glutamine or glutamic acid, as well as salts, amides, di- or tripeptides of the mentioned substances.Type: ApplicationFiled: November 15, 2006Publication date: December 17, 2009Applicant: Entress ABInventor: Stefan G. Pierzynowski
-
Patent number: 7632523Abstract: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.Type: GrantFiled: September 11, 2006Date of Patent: December 15, 2009Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Publication number: 20090306211Abstract: The present invention concerns a peritoneal dialysis fluid with enhanced ultrafiltration during the dialysis dwell period. According to the present invention this is achieved by a peritoneal dialysis fluid comprising sodium ions, osmotic agent and a buffer, characterised in that it comprises citrate at a level of 4 to 10 mM in a final solution ready for use.Type: ApplicationFiled: May 3, 2006Publication date: December 10, 2009Inventors: Anders Wieslander, Ola Carlsson, Magnus Braide, Per Kjellstrand
-
Publication number: 20090306002Abstract: An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided.Type: ApplicationFiled: June 11, 2009Publication date: December 10, 2009Applicant: AJINOMOTO CO. INCInventors: Takeshi Nakanishi, Takahiro Kuragano, Nobuhide Akaike, Takashi Nakanishi
-
Patent number: RE41279Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.Type: GrantFiled: March 2, 2006Date of Patent: April 27, 2010Assignee: Ecolab Inc.Inventors: David D. McSherry, Francis L. Richter
-
Patent number: RE41339Abstract: Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl compounds are useful to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.Type: GrantFiled: November 1, 2006Date of Patent: May 18, 2010Assignee: Tristrata, Inc.Inventors: Ruey J. Yu, Eugene J. Van Scott